The Hague, June 25, 2020, SPA -- European Medicine Agency (EMAs) human medicines committee (CHMP) has recommended granting a conditional marketing authorization to Remdesivir for the treatment of COVID-19 in adults and adolescents from 12 years of age, with pneumonia who require supplemental oxygen, provided the recommendation is endorsed by the European Commission. Remdesivir is the first medicine against COVID-19 to be recommended for authorization, in the EU. Data on Remdesivir were assessed in an exceptionally short timeframe through a rolling review procedure, an approach used by EMA during public health emergencies to assess data as they become available. --SPA 20:09 LOCAL TIME 17:09 GMT 0019 www.spa.gov.sa/w1357746